P115 A phase 2 multicenter study of the investigational single agent orteronel (ortl, TAK-700) in nonmetastatic castration-resistant prostate cancer (nmCRPC) and rising prostate-specific antigen (PSA)
Hussain, M., Corn, P.G., Michaelson, D., Hammers, H.J., Alumkal, J.J., Ryan, C.J., Bruce, J.Y., Moran, S., Lee, S.Y., Mortimer, P., George, D.J.Volume:
11
Language:
english
Journal:
European Urology Supplements
DOI:
10.1016/S1569-9056(13)60481-9
Date:
November, 2012
File:
PDF, 75 KB
english, 2012
File converter
More search results
More benefits 
